BioPortfolio - Xenova
Xenova - Entry on Bioportfolio's Biocorporate Database.
http://www.bioportfolio.com/biocorporate/25406-Xenova.html...
|
Editorial Overview
Bunce@xenova.com. 2. Duke University Medical Center. Division of Medical Oncology. Box 3233 Room 3803. Red Zone. Duke South Clinics. Durham. NC 27710 ...
http://www.biomedcentral.com/content/pdf/cd-646616.pdf...
|
BioPortfolio - Xenova - Profile
Xenova Biomanufacturing, the Company also undertakes contract manufacturing and process ... Xenova Group plc, 310 Cambridge Science Park, UK.- J Gene Med. ...
http://www.bioportfolio.com/biocorporate/32141-Xenova.pdf...
|
Xenova and Cantab Merge - Nature Biotechnology
On 19 February, two troubled UK-based biopharmaceutical companies, Xenova ( Slough) and Cantab (Cambridge), announced plans to merge in an all-share deal
...
http://www.nature.com/nbt/journal/v19/n4/full/nbt0401_297d.h...
|
BioPortfolio - Xenova - Profile
Xenova Group Limited, a fully-owned subsidiary of Celtic Pharma Development plc, ... Xenova Group plc, 310 Cambridge Science Park, UK.- J Gene Med. ...
http://www.bioportfolio.com/biocorporate/25406-Xenova.pdf...
|
BioSpace - Xenova Group PLC News, Search Jobs, Events
Xenova Group PLC 957 Buckingham Avenue Slough Berkshire SL1 4NL United Kingdom Phone: 01753-706-600 Fax: 01753-706-607 ...
http://www.biospace.com/company_profile.aspx?CompanyID=2880...
|
BioPortfolio - Xenova Group PLC
16 Nov 2008 ... Xenova Group PLC - Entry on Bioportfolio's Biocorporate Database.
http://www.bioportfolio.com/biocorporate/11097-Xenova_Group_...
|
TA-CD Xenova Christine E Heading
by Xenova (formerly Cantab) for the potential treatment of cocaine ..... escalation trial for anti-cocaine addiction vaccine TA-CD. Xenova Group ...
http://www.biomedcentral.com/content/pdf/cd-468427.pdf...
|
Jones Day - Experience - Tender offer for Xenova
Representation: Tender offer for Xenova Lead Practice(s): M&A September 2005. Summary: $47.5 million tender offer for and acquisition of Xenova Group plc ...
http://www.jonesday.com/experience/experience_detail.aspx?ex...
|
Technology evaluation: T-cell activator, Xenova Keith L Knutson
Pursuant to the agreement, Cantab (now Xenova) has the option to acquire exclusive worldwide rights to patent applications ...
http://www.biomedcentral.com/content/pdf/cd-433547.pdf...
|
